Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers.

Autor: Popovtzer A; Hadassah Medical Center, Ein Kerem 9112001, Israel., Mizrachi A; Rabin Medical Center, Derech Ze'ev Jabotinsky St., 39, Petah Tikva 4941492, Israel., D'Andrea MA; University Cancer Centers, 12811 Beamer Rd, Houston, TX 77089, USA., VanderWalde NA; West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, USA., Kurman N; Rabin Medical Center, Derech Ze'ev Jabotinsky St., 39, Petah Tikva 4941492, Israel., Rosenfeld E; Rabin Medical Center, Derech Ze'ev Jabotinsky St., 39, Petah Tikva 4941492, Israel., Ben-Hur R; Rabin Medical Center, Derech Ze'ev Jabotinsky St., 39, Petah Tikva 4941492, Israel., Bellia SR; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Feliciani G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Silvern D; Rabin Medical Center, Derech Ze'ev Jabotinsky St., 39, Petah Tikva 4941492, Israel., Sarnelli A; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Ballo MT; West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, USA., Patra P; West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, USA., Cohen GN; Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY 11553, USA., Damato AL; Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY 11553, USA., Shkedy Y; Rambam Healthcare Campus, HaAliya HaShniya St 8, Haifa 3109601, Israel., Den RB; Department of Radiation Oncology, Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.; AlphaTau Medical, Kiryat HaMada St 5, Jerusalem 9777605, Israel., Barker CA; Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY 11553, USA., Charas T; Rambam Healthcare Campus, HaAliya HaShniya St 8, Haifa 3109601, Israel., Hirshoren N; Hadassah Medical Center, Ein Kerem 9112001, Israel.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Jun 24; Vol. 16 (13). Date of Electronic Publication: 2024 Jun 24.
DOI: 10.3390/cancers16132312
Abstrakt: The initial favorable efficacy and safety profile for Alpha DaRT have been demonstrated (NCT04377360); however, the longer-term safety and durability of the treatment are unknown. This pooled analysis of four prospective trials evaluated the long-term safety and efficacy of Alpha DaRT for the treatment of head and neck or skin tumors. A total of 81 lesions in 71 patients were treated across six international institutions, with a median follow-up of 14.1 months (range: 2-51 months). Alpha DaRT sources were delivered via a percutaneous interstitial technique and placed to irradiate the tumor volume with the margin. The sources were removed two to three weeks following implantation. A complete response was observed in 89% of treated lesions (n = 72) and a partial response in 10% (n = 8). The two-year actuarial local recurrence-free survival was 77% [95% CI 63-87]. Variables, including recurrent versus non-recurrent lesions, baseline tumor size, or histology, did not impact long-term outcomes. Twenty-seven percent of patients developed related acute grade 2 or higher toxicities, which resolved with conservative measures. No grade 2 or higher late toxicities were observed. These data support the favorable safety profile of Alpha DaRT, which is currently being explored in a pivotal US trial.
Databáze: MEDLINE
Externí odkaz: